Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The combination of ketaconazole and hydrocortisone is commonly used for the treatment of
prostate cancer. The purpose of this study is to determine if the addition of a drug called
dutasteride to this approved combination will make the combination more effective in treating
prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Dana-Farber Cancer Institute M.D. Anderson Cancer Center Massachusetts General Hospital Oregon Health and Science University Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sunnybrook Health Sciences Centre